Pricing Log in Create free account
Saturday 17 October 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Zoetis Inc. (ZTS) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 8, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K Oct 8, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 6, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 42 added · 15 removed · 43 modified
P2I1A: no comparison — incorporated by reference
8-K Aug 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 20, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders
8-K May 20, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 8 added · 2 removed · 51 modified
1A: 18 added · 4 removed · 58 modified
7: 33 added · 26 removed · 59 modified
8-K Feb 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 5, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Dec 15, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 3.02 Unregistered sales of equity securities; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Dec 11, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Dec 2, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 23, 2025 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Oct 9, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 27, 2025 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.